This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Tedeschi, R. Articles by De Paoli, P. Search for Related Content PubMed PubMed Citation Articles by Tedeschi, R. Articles by De Paoli, P.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, May 1996, 363-364, Vol 3, No. 3
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Antibody responses to defined epitopes in the Epstein-Barr virus BZLF1- encoded transactivator protein among human immunodeficiency virus- infected patients

R Tedeschi, J Dillner and P De Paoli
Microbiology-Immunology and Virology Division, Istituto Nazionale di Ricovero e Cura a Carattere Scientifico, Aviano, Italy.

The Epstein-Barr virus BZLF1-encoded replication activator (ZEBRA) is a key mediator of reactivation from latency to the viral productive cycle. In the present study, the serum antibody responses against three defined ZEBRA epitopes (designated ZEBRA-1, -19, and -22) were determined for 50 human immunodeficiency virus (HIV)-seropositive patients and 100 matched healthy control subjects. The anti-ZEBRA responses were more commonly found among HIV-seropositive patients than among healthy controls for all the three ZEBRA epitopes tested (P < 0.0003, P < 0.003, and P < 0.001, respectively). Comparison of ZEBRA antibody levels with the degree of immunodeficiency (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.